Loading clinical trials...
Loading clinical trials...
A PHASE 2b, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE
Conditions
Interventions
RSV Vaccine
Tdap
+1 more
Locations
16
United States
Clinical Research Atlanta
Stockbridge, Georgia, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Alliance for multispecialty research
Wichita, Kansas, United States
Sundance Clinical Research
St Louis, Missouri, United States
Meridian Clinical Research
Omaha, Nebraska, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Start Date
October 1, 2019
Primary Completion Date
December 11, 2019
Completion Date
December 11, 2019
Last Updated
February 15, 2021
NCT07297966
NCT06282718
NCT06788093
NCT07278700
NCT07249996
NCT06560255
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions